A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations

  • Kwan, Edmond (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/16/SVHM/251
NMA SSA Reference Number: SSA/17/MonH/55
Monash Health Ref: 17-0000-065X
Effective start/end date25/03/1922/06/20


  • clinical trial
  • phase 3 study
  • treatment efficacy
  • prostate cancer